Orphan Australia: Product Info

Product list quick links

Brand	Other Names	Presentation	Strengths	Enquire
Actiq ®	fentanyl citrate	Oral lozenges	200 mcg; 3 lozenges
		Oral lozenges	400 mcg; 3 lozenges
		Oral lozenges	600 mcg; 3 lozenges
		Oral lozenges	800 mcg; 3 lozenges
		Oral lozenges	1200 mcg; 3 lozenges
		Oral lozenges	1600 mcg; 3 lozenges

TGA indication
Actiq is indicated for the management of breakthrough cancer pain in patients with malignancies who are already receiving and are tolerant to opioid therapy for their underlying persistent cancer pain.

PBS listing

INITIAL SUPPLY: Authority required.

Initial supply for dose titration for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.

Note: No applications for increased repeats will be authorised.

FIRST CONTINUING SUPPLY: Authority required.

First continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects;

Second and subsequent continuing supply (for up to 3 months) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects, where consultation with a palliative care specialist or service has occurred.

Note: No applications for increased repeats will be authorised.
Telephone approvals are limited to 1 month's therapy.

SECOND AND SUBSEQUENT CONTINUING SUPPLY: Authority required.

Second and subsequent continuing supply (for up to 1 month) for breakthrough pain in palliative care patients with cancer who are receiving opioids for their persistent pain and where further escalation in the dose of morphine for breakthrough pain results in intolerable adverse effects.

Note: No applications for increased repeats will be authorised.

Information for Patients
Consumer Medicine Information	Actiq_CMI.pdf

Information for Healthcare Professionals
Product Information	Actiq_PI.pdf